Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relay Therapeutics Inc (NQ: RLAY )

5.840 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 105
Open 5.840
Bid (Size) 5.500 (5)
Ask (Size) 5.840 (1)
Prev. Close 5.840
Today's Range 5.840 - 5.840
52wk Range 5.600 - 12.14
Shares Outstanding 121,613,181
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets

Performance

YTD
-50.74%
-50.74%
1 Month
-10.57%
-10.57%
3 Month
-17.75%
-17.75%
6 Month
-17.28%
-17.28%
1 Year
-28.17%
-28.17%

More News

Read More
Why Relay Therapeutics Plummeted by Nearly 14% Today
Via The Motley Fool
Why Relay Therapeutics (RLAY) Stock Is Down 17% Today
Via Benzinga
Expert Ratings For Relay Therapeutics
Via Benzinga
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Via Benzinga
GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why Dave & Buster's Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market
Via Benzinga
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
Via Talk Markets
This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Dow Jumps Over 1% Following Last Week's Selloff: Investor Sentiment Improves, But Fear & Greed Index Remains In 'Fear' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
Relay Therapeutics Announces Proposed Public Offering of Common Stock
From Relay Therapeutics, Inc.
Via GlobeNewswire
Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Nasdaq Surges Over 1%; US Wholesale Inventories Rise 0.2% In July
Via Benzinga
Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients
Via Benzinga
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
Via Benzinga
US Stocks Higher; Dow Surges Over 200 Points
Via Benzinga
Topics Stocks
Exposures US Equities
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
Via Talk Markets
Topics Economy
Exposures Economy
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
Via Talk Markets
RLAY Stock Earnings: Relay Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.